[Nonorganic hypersomnia: epidemiology, diagnosis, and therapy].
Daytime tiredness and daytime sleepiness are frequent complaints occurring in 29% and 14% of the Austrian population. Epidemiological studies demonstrate a high comorbidity between nonorganic hypersomnia and mental disorders. Especially comorbidity with affective disorders increases steadily from the general population over primary to tertiary care settings. Diagnostic criteria of nonorganic hypersomnia have been described in the International Classification of Diseases (ICD-10). Nonorganic hypersomnia can be primary or associated with a number of psychiatric disorders such as reaction to severe stress or adjustment disorders, affective disorders, other functional disorders, tolerance to or withdrawal of CNS-stimulating substances and chronic use of CNS-sedating substances. Diagnostic procedures comprise case history and symptom evaluation, sleep-specific and supplementary investigations. Concerning the latter, this article will focus on sleep questionnaires, vigilance and psychological tests as well as CNS investigations. Therapy of nonorganic hypersomnia rests on 3 pillars: psychological, somatic and pharmacological treatment. In view of the wide variety of psychiatric causes, resulting in a number of therapeutic options, it seems desirable that apart from subjective clinical assessment also objective methods be used in diagnosis and treatment. On the neurophysiological level objective measures can be obtained by means of EEG mapping during the day and polysomnography at night. Different mental disorder patients show different brain activity patterns as compared with normal controls and different classes of psychotropic substances cause different changes in neurophysiological variables. The fact that the changes in electrophysiological brain activity caused by mental disorders are exactly opposite to those induced by the psychotropic drugs used for their treatment suggests a key-lock principle in the diagnosis and treatment of nonorganic hypersomnia.
Saletu
B
B
Bereich für Schlafforschung und Pharmakopsychiatrie, Universitätsklinik für Psychiatrie, Wien, Osterreich. bernd.saletu@akh-wien.ac.at
Anderer
P
P
Saletu-Zyhlarz
G M
GM
D001317:Austria / Q000453:epidemiology; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D001931:Brain Mapping; D015897:Comorbidity; D003937:Diagnosis, Differential; D006970:Disorders of Excessive Somnolence / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy; D004569:Electroencephalography / Q000187:drug effects*; D006801:Humans; D001523:Mental Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology*; D009483:Neuropsychological Tests; D017286:Polysomnography; D017410:Practice Guidelines as Topic; D011619:Psychotropic Drugs / Q000494:pharmacology*
D011619:Psychotropic Drugs